FGF-2 variants and methods of use thereof
US9487568B2 · kind B2 · utility
0Cited by
34References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 19, 2014 |
| Grant date | Nov 8, 2016 |
| Priority date | — |
| Expiry date | Nov 19, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2506/1346
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating an individual (i) having abnormal bone; or (ii) afflicted with a disease or disorder related to normal or abnormal FGF receptors or a skeletal disorder; or (iii) having dysplasic bone. The method includes administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a fibroblast growth factor 9 (FGF-9) variant comprising at least one amino acid substitution in the beta 8-beta 9 loop, wherein said FGF-9 variant incorporates one of the amino acid sequences set forth in SEQ ID NO: 11, 13, 14, 15, 16 or 17.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.